DYAX 13.50 Dyax Corp $DYAX Hit a 52 week high of 13.66

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 11:29 AM

DYAX 13.50 Dyax Corp $DYAX Hit a 52 week high of 13.66 Closing the day 09:44 at 13.50 +0.03 +0.22% With a day low of 13.43 and a total volume of 52,446.

DYAX Recent Posts: http://investorshangout.com/Dyax-Corp-DYAX-53955/

DYAX Dyax Corp Recent Headline News

Dyax Up 73.8% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Mon Nov 10, 4:46PM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 6 months, Dyax has returned 73.76% as of today's recent price of $13.18.
DYAX: 13.35 (-0.12)

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 13.35 (-0.12)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 13.35 (-0.12)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 13.35 (-0.12)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 13.35 (-0.12)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 319.06 (-1.96), AMAG: 34.76 (-0.17), BIND: 10.05 (+0.07), DYAX: 13.35 (-0.12)

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright
David Zanoni - at Seeking Alpha - Thu Oct 30, 11:15AM CDT

DYAX: 13.35 (-0.12)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 13.35 (-0.12)

Dyax ups earnings 87% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:53AM CDT

DYAX: 13.35 (-0.12)

Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 7:54PM CDT

DYAX: 13.35 (-0.12)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 13.35 (-0.12)

Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT

DYAX: 13.35 (-0.12)

Dyax beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:16PM CDT

DYAX: 13.35 (-0.12)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.35 (-0.12)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:35PM CDT

EA: 41.40 (+0.20), BXP: 127.35 (+0.55), AMP: 129.99 (-0.29), MRCY: 13.53 (-0.10), BLDP: 2.55 (unch), ESRX: 77.63 (-0.21), AJG: 48.25 (+0.35), NANO: 14.19 (+0.06), CAP: 22.64 (-0.06), EXTR: 3.74 (-0.01), HTA: 12.48 (+0.08), AEC: 19.58 (+0.10), MCK: 204.51 (+1.38), BGFV: 13.30 (-0.08), FB: 74.15 (-0.57), ARI: 16.49 (-0.01), EXP: 85.76 (-1.75), MWA: 9.83 (-0.11), DYAX: 13.35 (-0.12), FARO: 55.60 (-0.90), NFX: 32.42 (-0.69), KONA: 23.02 (+0.01), AZPN: 37.72 (-0.07), GILD: 103.93 (-2.97), HIW: 42.17 (-0.11), PEI: 21.76 (+0.22), GFIG: 4.86 (+0.01), CHRW: 72.91 (+0.05), HURN: 69.39 (-0.86), DLR: 68.60 (+0.20), HLIT: 6.87 (-0.03), AMCC: 6.24 (-0.10), INVN: 14.27 (+0.01), BOOM: 17.07 (-0.21), CINF: 51.55 (+0.28), KIM: 24.85 (+0.25), OI: 25.58 (-0.30), GPRE: 33.16 (-0.45), EPR: 56.84 (+0.25), APC: 89.23 (-2.19), IPHI: 14.36 (-0.17), HTS: 19.08 (-0.02), MAR: 77.82 (+0.52), INAP: 7.98 (-0.02), CRAY: 34.09 (-0.36), FEIC: 82.62 (-0.47), FISV: 70.28 (+0.43), DNB: 124.97 (-0.04), AFG: 60.55 (+0.08), CEB: 74.97 (-0.49), KEYW: 10.91 (-0.07), PLT: 52.08 (-0.31), MAC: 68.93 (+0.33), CHMT: 23.42 (-0.07), AFL: 59.17 (-0.04), CBT: 46.70 (-0.67), EIX: 62.32 (-0.08), EQR: 69.92 (+0.61)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 13.35 (-0.12)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.58 (+0.37), BCRX: 10.74 (-0.04), NBIX: 19.20 (-0.08), ONTY: 1.73 (+0.01), DYAX: 13.35 (-0.12)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 13.35 (-0.12)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ

YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 13.35 (-0.12)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 13.35 (-0.12)

Dyax Corp. (DYAX) Stock Research Links

DYAX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LogiSense Secures Top Spot in 2026 Billing Solutions Guide

LogiSense Gets High Marks in MGI Research Guide Well, here we go. LogiSense is making waves in the enterprise billing scene, snagging a top-five spot in MGI Research's 2026 Agile Billing Top 50 Buyer's Guide. The Kitchener-based outfit has been recognized not just for its strength in handling billing volumes, but for its top-notch capability in solution strength. Their...

Heineken Hit with €111M Judgment—A Precedent Set

A Brew of Legal Consequences for Heineken If this isn't a financial wake-up call for the brewing giant, I don't know what is. In the latest twist of corporate accountability, the Amsterdam District Court has ordered Heineken and its Greek subsidiary, Athenian Brewery, to cough up a whopping €111 million. And we're not just talking pocket change—this ruling speaks...

Rising Demand for Natural Fibres: Woolmark's Bold Move

A Shift Toward Nature-Driven Choices There's something brewing in the fashion world that signals a deeper shift—a movement toward fibers that feel real, fibers that nature and time have refined. Recent Ipsos research commissioned by Woolmark has laid bare the growing consumer preference across major markets, with a distinct swing towards natural fibers, leaving...

Microtubule Defects Revealed: Impacts on Cancer Treatment

Peering into the Heart of Microtubules Ever squint at a tapestry, only to find a rogue thread ruining the pattern? Well, that’s somewhat what scientists at Kanazawa University have found with microtubules, those tiny rods in our cells that usually keep it all together. Using some pretty fancy tech called high-speed atomic force microscopy, these folks peered into the...

ManpowerGroup to Feature at J.P. Morgan Conference

ManpowerGroup Heads to the Big Apple ManpowerGroup's top brass are packing their bags for New York City, heading to the J.P. Morgan Ultimate Services Investor Conference. Now, this isn’t just another cookie-cutter investor meet-up. Jack McGinnis, the CFO, and Becky Frankiewicz, the President and Chief Strategy Officer, are slated to have a fireside chat on November 17,...

Highlight's Pulse Offers Real-Time Consumer Insights

Highlight Introduces Pulse for Instant Insights Ever find yourself waiting forever for consumer feedback? Well, folks, Highlight's making sure those days are behind us with their new launch: Pulse. They've taken the conventional consumer testing model and flipped it on its head with Highlight Twins. Imagine getting the pulse of your audience in mere seconds, not the...

Plaid Eyes Data Horizons; Acorns Embraces Gen Z

Fintech's Next Frontier: Plaid's Vision You ever get the feeling some folks see further down the road than others? That's Plaid CTO Will Robinson, chatting up the NYSE folks at Money20/20. The man’s got his eyes on what he calls "making sense" of financial data—no small feat in our swamped digital world. Plaid ain't some penny stock operation, either. This is an $8...

AT&T Surges with Major Revenue Boost and Fiber Expansion

AT&T's stirring up the pot with a third-quarter blowout that even the cleverest of market watchers had to tip their hats to. Barely anyone had five years ago pegged the sleepy telecom to launch past some of the juggernauts in service revenue growth. But here we are, folks—the company clocking a solid $32.3 billion in revenue, trundling in at a thick 5.3% from the...

Nelson-Jameson Opens New Doors in Food Safety Service

Navigating the Food Safety Landscape Well, they say timing's everything in this business, and Nelson-Jameson just struck gold by being the first to buddy up with Strahman Group® as an Authorized Service Provider. You see, in the rollercoaster world of food processing, having a reliable partner to keep your equipment in tip-top shape can be the game-changer. If you're...

Strategic Moves in Biotech: The EQT-Qiagen Deal EQT Private Equity's latest maneuver has seasoned investors raising an eyebrow. They've just put an all-cash public takeover offer on the table for Qiagen, and no, this isn't your run-of-the-mill acquisition—it's a play steeped in strategy and capital dynamics. EQT's Portfolio Puzzle: Where Does Qiagen Fit? Let's break it...